Aspire Biopharma Holdings Inc Stock Price, News & Analysis

Aspire Biopharma Holdings (NASDAQ:ASBP) announced significant leadership changes, with Chairman Kraig Higginson appointed as interim CEO effective July 24, 2025, following Michael C. Howe's resignation from both CEO position and Board membership.

The company also announced the immediate resignations of Board members Gary E. Stein and Barbara Sher. In a key appointment, Howard Doss, a seasoned financial executive with extensive experience at companies like PowerUp and Trade Health, has joined as Director and Chairman of the Audit Committee.

Higginson, who previously served as CEO for four years, expressed commitment to executing the company's strategy focused on its drug delivery platform technology.

Aspire Biopharma Holdings (NASDAQ:ASBP) announced the launch of its new pre-workout supplement BUZZ BOMB™ at two major fitness conventions - FitCon in Salt Lake City (August 1-2) and FitExpo in Anaheim (August 2-3, 2025).

The product features 50mg of caffeine delivered through sublingual nano technology, offering nearly instant energy through easy-to-use packets. As a Gold Sponsor at FitCon (20,000 attendees) and sponsor at FitExpo (33,000 attendees), BUZZ BOMB™ will receive prominent placement, extensive marketing exposure, and product sampling opportunities to all attendees.

The company aims to disrupt the multi-billion-dollar pre-workout market with its innovative delivery system that provides immediate effects compared to traditional pre-workout supplements that require 20-30 minutes to activate.

Aspire Biopharma Holdings (NASDAQ:ASBP) has announced positive consumer feedback for its new pre-workout supplement BUZZ BOMB™. The product features a patent-pending sublingual delivery technology with 50mg of caffeine designed for rapid absorption and immediate effect.

The company has completed initial production in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Mocha Coffee) and plans to launch at major fitness conventions in August. BUZZ BOMB™ is packaged in single-serving packets and targets the pre-workout supplement market, projected to reach $27.97 billion by 2030.

CEO Michael Howe indicated this launch represents the first step in Aspire's strategy to leverage its sublingual nano technology, with plans to introduce additional nutraceutical and supplement products while exploring licensing opportunities.

Aspire Biopharma Holdings (NASDAQ:ASBP) has completed patient dosing in its Phase 1 clinical trial for its oral transmucosal fast-acting high-dose aspirin formulation. The study compares the company's sublingual 162.5 mg aspirin powder against traditional oral aspirin in healthy adult volunteers.

The trial evaluates plasma acetylsalicylic acid concentration, Arachidonic acid-induced platelet aggregation, and Serum thromboxane B2 measurements to assess the formulation's rapid impact on cardiac events. Topline results are expected by mid-Q3 2025, after which Aspire plans to pursue a section 505(b)(2) NDA and explore potential partnership opportunities.

Aspire Biopharma Holdings (NASDAQ: ASBP) has appointed Michael C. Howe as its new Chief Executive Officer, effective June 10, 2025. Howe, who currently serves as an Independent Board Member, brings over four decades of experience in healthcare and consumer brands. His notable achievements include transforming MinuteClinic from 19 clinics to over 530 locations after its CVS acquisition, delivering a sixfold return for investors. Former CEO Kraig Higginson will transition to Executive Chairman. Howe's appointment comes at a crucial time as Aspire advances its drug delivery technology platform, conducts FDA clinical trials for high-dose aspirin via the 505(b)(2) pathway, and prepares to launch its pre-workout supplement, BUZZ BOMB™, in 2025.

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the upcoming launch of BUZZ BOMB™, a novel sublingual pre-workout supplement, in Q3 2025. The product features 50mg of caffeine delivered through proprietary sublingual nano technology, offering rapid absorption directly into the bloodstream. Initial production has begun with six flavor options, including Tropical Fruit, Mixed Berry, Watermelon, Lemon Lime, Peach Mango, and Mocha Coffee. The company plans expanded pre-launch consumer testing in Q2 2025 and will showcase the product at two major fitness conventions in August 2025. BUZZ BOMB™ differentiates itself through immediate effectiveness, convenient single-serving packets, and on-demand energy management. The global pre-workout supplements market is projected to reach $27.97 billion by 2030, with a CAGR of 5.9% from 2025-2030.

Aspire Biopharma Holdings (NASDAQ: ASBP) has initiated its Phase 1 clinical trial for its lead product, a novel oral transmucosal fast-acting high-dose aspirin formulation. The single-center U.S. trial has dosed its first patient and aims to evaluate safety, pharmacokinetics, and pharmacodynamics. The study will compare a 162.5 mg sublingual aspirin powder/granules against conventional oral aspirin in healthy adult volunteers. The trial's primary focus is measuring plasma acetylsalicylic acid concentration over 24 hours, along with TxB2 and anti-coagulant bioavailability data. Completion is expected by mid-June 2025, with topline data anticipated in early Q3 2025. If successful, the trial could support accelerated FDA approval.

Aspire Biopharma Holdings (NASDAQ:ASBP), a developer of patent-pending drug delivery technology, has announced its participation in the upcoming Sidoti Virtual Investor Conference. CEO Kraig Higginson will deliver a presentation on May 21, 2025, at 2:30 PM Eastern. The company will also host one-on-one meetings with investors on May 21-22, 2025.

Interested participants can access the virtual presentation through Sidoti's registration link, and a replay will be available on Aspire's investor relations website. This conference provides an opportunity for investors to learn more about Aspire's multi-faceted drug delivery technology and engage directly with management.

Aspire Biopharma (Nasdaq: ASBP) has received Institutional Review Board (IRB) approval for its Phase I clinical trial of a novel oral transmucosal fast-acting high-dose aspirin formulation. The trial, set to begin this week, will involve 6-8 participants at a single U.S. center.

The study will compare a 162.5 mg sublingual aspirin powder against standard oral aspirin in healthy adult volunteers, measuring plasma acetylsalicylic acid concentration over 24 hours. This innovative delivery method aims to bypass first-pass metabolism through oral mucosa absorption.

The company plans to pursue FDA fast-track approval via a 505(b)(2) NDA for treating suspected acute myocardial infarction. Previous research has shown aspirin treatment reduced vascular mortality risk by 23% in MI patients. The new formulation could potentially offer improved bioavailability while limiting gastric irritation associated with traditional aspirin delivery.